Eikon Therapeutics, Inc. (NASDAQ:EIKN) Receives Average Recommendation of “Hold” from Analysts

Eikon Therapeutics, Inc. (NASDAQ:EIKN) has earned a consensus rating of “Hold” from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $25.20.

A number of equities analysts recently commented on EIKN shares. Cantor Fitzgerald restated an “overweight” rating on shares of Eikon Therapeutics in a report on Tuesday, June 2nd. Wedbush reduced their price objective on shares of Eikon Therapeutics from $7.00 to $5.00 and set an “underperform” rating on the stock in a research report on Tuesday, May 12th. Wall Street Zen lowered shares of Eikon Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, April 5th. Finally, Weiss Ratings began coverage on shares of Eikon Therapeutics in a research report on Monday, June 1st. They issued a “sell (e-)” rating for the company.

Eikon Therapeutics Stock Performance

Shares of NASDAQ:EIKN opened at $12.54 on Friday. The firm’s 50-day simple moving average is $10.32. The stock has a market cap of $678.90 million and a P/E ratio of -5.10. Eikon Therapeutics has a 1 year low of $7.90 and a 1 year high of $17.40.

Eikon Therapeutics (NASDAQ:EIKN) last released its quarterly earnings data on Monday, March 30th. The company reported ($26.23) earnings per share for the quarter.

Eikon Therapeutics Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.